Igen International Inc.

They're more well-established than their 2000 predecessors, but what do investors think of them? By Heather Slowik A new breed of biotech companies has emerged for this latest opening of the IPO windo

In this issue, we present another installment of our quarterly review of dealmaking—for July-September 2003. Our data comes from Windhover's Strategic Transactions Database , which covers deal activi

Investors are looking more favorably at diagnostics than they have in years—driven in part by major success stories despite tumultuous public and private markets. In the public markets, Gen-Probe Inc

Roche 's $1.4 billion deal to buy Igen International Inc. [See Deal] left Igen shareholders gleeful to say the least and some Roche observers a bit wary of the high price tag and generous terms.